Law360 (May 7, 2018, 6:19 PM EDT) — The Patent Trial and Appeal Board on Friday said it wouldn’t reevaluate an Astellas Pharma Inc. patent covering the overactive bladder treatment … 6,346,532, concluding that Sawai USA Inc. was unlikely to be able to prove that the patent was invalid as obvious.
